Scopus h-index:26
- Home
- Profiles
Megan L Shaw, PhD
- About Me
- Education & Certifications
- Research
- Locations
- Publications
- Industry Relationships
About Me
Language
Position
Research Topics
Antivirals, Biodefense, Immune Antagonism, Infectious Disease, Influenza Virus, Nipah Virus, Viruses and Virology
Multi-Disciplinary Training Areas
Microbiology [MIC]
About Me
Language
Position
Research Topics
Antivirals, Biodefense, Immune Antagonism, Infectious Disease, Influenza Virus, Nipah Virus, Viruses and Virology
Multi-Disciplinary Training Areas
Microbiology [MIC]
About Me
Language
Position
Research Topics
Antivirals, Biodefense, Immune Antagonism, Infectious Disease, Influenza Virus, Nipah Virus, Viruses and Virology
Multi-Disciplinary Training Areas
Microbiology [MIC]
Education
BSc, University of Cape Town
BSc (Med)Honors, University of Cape Town
PhD, University of Glasgow
Research
The Shaw laboratory is interested in the interactions that occur between RNA viruses and their hosts at the molecular level and how this knowledge may be used for understanding viral pathogenesis and for developing new antiviral drugs. The research involves basic molecular biology and virology techniques combined with RNAi, proteomics and high-throughput screening of small molecular weight compounds.
Our major focus is on identifying new antivirals for influenza virus as well as host proteins that are required by the virus and therefore may serve as novel drug targets. Another interest of the Shaw lab is the host antiviral response and specifically the mechanisms that viruses use to block this response. One virus of particular interest to us is Nipah virus, with is a highly pathogenic, emerging paramyxovirus. Nipah virus encodes multiple proteins that inhibit the antiviral response and our goal is to determine their mechanisms of action and their individual contributions to virus pathogenesis.
Locations
Publications
Article:34
Review Article:5
Comment/Debate:1
Letter:1
Editorial:1
Chapter:4
Selected Publications
- A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
- Common and species-specific molecular signatures, networks, and regulators of influenza virus infection in mice, ferrets, and humans
- Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
- Functional landscape of SARS-CoV-2 cellular restriction
- Enisamium Reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity
- High burden of viral respiratory co-infections in a cohort of children with suspected pulmonary tuberculosis
- An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes with Oseltamivir
- Baloxavir marboxil: the new influenza drug on the market
- Influenza
- SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Shaw during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Farmak
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.